Pancreatic cancer survival trends overall, by stage, and histologic sub-type: An analysis of Surveillance, Epidemiology and End Results (SEER) population-based data (2000-2015).

e15772 Background: Pancreatic cancer (PC) is the third leading cause of cancer mortality in the United States, with an overall relative 5-year survival rate of 8.2%. We conducted a comprehensive evaluation of survival trends after PC diagnosis overall and by stage and histologic sub-type. Methods: We conducted a retrospective, population-based study of 91,234 PC cases using nationally representative data from the SEER program to evaluate 5-year survival trends by histologic sub-type from 2000 to 2015. Our model incorporated sub-type-specific random intercepts to effectively stabilize survival estimates by borrowing information across all sub-types. The estimation was performed in a fully Bayesian setting in R. Results: Adenocarcinoma, not otherwise specified (NOS) and ductal adenocarcinomas comprised 81% of PC. Cancer stage and histologic sub-type were both important factors in explaining variability in 5-year survival. We observed a consistent ordering of cancer stages within each histologic sub-type from highest to lowest survival for local, regional, and metastatic disease, respectively. Adenocarcinoma not otherwise specified, ductal adenocarcinoma, ductal specified as mucinous, and poorly specified type had the lowest 5-year survival with fitted ranges of 25-35% for localized, 5-19% for regional and < 4% for metastatic disease. Ductal arising from intraductal papillary mucinous neoplasm, ductal specified as cystic, acinar cell, other adenocarcinoma, and non-carcinomas had intermediate 5-year survival of 54-75%; while endocrine non-secretory or neuroendocrine, endocrine secretory, carcinoid, and solid pseudopapillary cancers had the best survival (87-98%). On average, across histologic sub-types, PC survival improved by 0.5% (90% credible interval 0.01%, 1.0%) per year, or 5.1% (0.1%, 10.0%) per decade. Some improvement in fitted survival occurred across all stages and histologic sub-types. Conclusions: Overall survival for patients with PC has improved by around 5% per decade from 2000 to 2015, with significant heterogeneity by histologic sub-type.

Download Full-text

Cancer Survival Is (Mostly) Improving

Pained ◽

10.1093/oso/9780197510384.003.0070 ◽

2020 ◽

pp. 245-246

Author(s):

Michael D. Stein ◽

Sandro Galea

Keyword(s):

Prostate Cancer ◽

United States ◽

Pancreatic Cancer ◽

Survival Rate ◽

Cancer Diagnosis ◽

Cancer Survival ◽

Prostate Cancer Screening ◽

Survival Rates ◽

The United States ◽

Cervical Cancers

This chapter discusses how the 5-year survival rates for the most common cancers in the United States improved by nearly 20% since the 1970s. While promising overall, low survival rates persist for pancreatic, liver, lung, esophageal, brain, and many other cancers. Meanwhile, 5-year survival for uterine and cervical cancers worsened. Pancreatic cancer has the lowest 5-year survival rate at 8.2%. In contrast, prostate cancer had the greatest 5-year survival increase from 67.8% to 98.6%, most likely reflecting a substantial uptick in prostate cancer screening and early detection. Five-year survival with leukemia also improved significantly, from 34.2% to 60.6%, likely resulting from improved treatments. As such, in both detection and treatment, the United States is making progress. For the millions of Americans who face a cancer diagnosis, this is cause for hope.

Download Full-text

Temporal trends of pancreatic ductal adenocarcinoma in young adults in the United States: A Population-Based Study

Clinics and Research in Hepatology and Gastroenterology ◽

10.1016/j.clinre.2019.07.001 ◽

2020 ◽

Vol 44 (2) ◽

pp. 204-210

Author(s):

Mohamed M. Gad ◽

Anas M. Saad ◽

Muneer J. Al-Husseini ◽

Youssef M. Abdel-Gawad ◽

Obai M. Alsalhani ◽

...

Keyword(s):

United States ◽

Young Adults ◽

Pancreatic Ductal Adenocarcinoma ◽

Temporal Trends ◽

The United States ◽

Population Based ◽

Ductal Adenocarcinoma ◽

Population Based Study

Download Full-text

Geographical residency influences pancreatic cancer survival: a Danish nationwide population-based cohort study

HPB ◽

10.1016/j.hpb.2018.06.1948 ◽

2018 ◽

Vol 20 ◽

pp. S533

Author(s):

J. Kirkegård ◽

M. Ladekarl ◽

C.W. Fristrup ◽

C. Palnæs-Hansen ◽

M. Sall ◽

...

Keyword(s):

Pancreatic Cancer ◽

Cohort Study ◽

Cancer Survival ◽

Population Based

Download Full-text

Occupational class differences in pancreatic cancer survival: A population‐based cancer registry‐based study in Japan

Cancer Medicine ◽

10.1002/cam4.2138 ◽

2019 ◽

Cited By ~ 3

Author(s):

Masayoshi Zaitsu ◽

Yongjoo Kim ◽

Hye‐Eun Lee ◽

Takumi Takeuchi ◽

Yasuki Kobayashi ◽

...

Keyword(s):

Pancreatic Cancer ◽

Cancer Registry ◽

Cancer Survival ◽

Population Based ◽

Occupational Class ◽

Class Differences

Download Full-text

Clinicopathologic Features and Outcome of Adenocarcinoma of the Anal Canal: A Population-Based Study

International Journal of Surgical Oncology ◽

10.1155/2020/5139236 ◽

2020 ◽

Vol 2020 ◽

pp. 1-6

Author(s):

Shekhar Gogna ◽

Roberto Bergamaschi ◽

Agon Kajmolli ◽

Mahir Gachabayov ◽

Aram Rojas ◽

...

Keyword(s):

Anal Canal ◽

Cancer Survival ◽

Young Patients ◽

The United States ◽

Population Based ◽

Incidence Rates ◽

Term Survival ◽

Impact On Survival ◽

Patient Groups ◽

Well Differentiated

Background. Anal canal adenocarcinoma (AA) is an uncommon tumor of the gastrointestinal tract. We seek to provide a detailed description of the incidence, demographics, and outcome of this rare tumor in the United States. Methods. The data on anal canal adenocarcinoma from SEER Program, between 1973–2015, were extracted. We analyzed the incidence rates by demographics and tumor characteristics, followed by analysis of its impact on survival. Results. The incidence of AA increased initially by 4.03% yearly from 1973 to 1985 but had a modest decline of 0.32% annually thereafter. The mean age for diagnosis of AA was 68.12 ± 14.02 years. Males outnumbered females by 54.8 to 45.2%. Tumors were mostly localized on presentation (44.4%) and moderately differentiated (41.1%). Age generally correlated with poor overall cancer survival. However, young patients (age <40 years) also showed poor long-term survival. Patients with localized disease and well-differentiated tumors showed better survival outcomes. Surgical intervention improved survival significantly as compared to patients who did not (116.7 months vs 42.7 months, p<0.01). Conclusions. Anal canal adenocarcinoma demonstrated a poor bimodal cancer-free survival in both younger and older patient groups. Surgery significantly improves odds of survival and should be offered to patients amenable to intervention.

Download Full-text

Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study

PLoS ONE ◽

10.1371/journal.pone.0202486 ◽

2018 ◽

Vol 13 (8) ◽

pp. e0202486 ◽

Cited By ~ 4

Author(s):

Jakob Kirkegård ◽

Morten Ladekarl ◽

Claus Wilki Fristrup ◽

Carsten Palnæs Hansen ◽

Mogens Sall ◽

...

Keyword(s):

Pancreatic Cancer ◽

Cohort Study ◽

Cancer Survival ◽

Population Based ◽

Rural Residency ◽

Urban Versus

Download Full-text

Clinical Scenarios Emerging from Combined Immunophenotypic, Molecular and Morphologic Analysis of Pancreatic Cancer: the Good, the Bad and the Ugly Scenario

Cancers ◽

10.3390/cancers11070968 ◽

2019 ◽

Vol 11 (7) ◽

pp. 968 ◽

Cited By ~ 1

Author(s):

Karamitopoulou ◽

Gloor

Keyword(s):

Pancreatic Cancer ◽

Immune Cell ◽

Ductal Adenocarcinoma ◽

Significant Heterogeneity ◽

Dismal Prognosis ◽

Clinical Scenarios ◽

Novel Biomarkers ◽

Morphologic Analysis ◽

Dynamic Interplay ◽

Immune Cell Infiltrates

: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with increasing incidence and dismal prognosis. The composition of the immune cell infiltrates in the tumor microenvironment (TME) and the dynamic interplay between cancer- and immune cells can influence and/or be influenced by tumor-intrinsic characteristics like molecular profiles and tumor cell morphology. The combined analyses of pancreatic cancer by using morphologic, genetic, and immunologic features help us understand the significant heterogeneity of the TME and recognize the different mechanisms of immune evasion. Moreover, this information may lead to the identification of novel biomarkers for more precise patient stratification and therapy guidance.

Download Full-text

The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer

Viruses ◽

10.3390/v12111318 ◽

2020 ◽

Vol 12 (11) ◽

pp. 1318

Author(s):

Scott D. Haller ◽

Michael L. Monaco ◽

Karim Essani

Keyword(s):

United States ◽

Pancreatic Cancer ◽

Surgical Resection ◽

Clinical Investigation ◽

Treatment Options ◽

Late Phase ◽

The United States ◽

Oncolytic Viruses ◽

Ductal Adenocarcinoma ◽

Treatment Regimens

Pancreatic ductal adenocarcinoma (PDAC) is the fifth leading cause of cancer-related death in Western countries. The incidence of PDAC has increased over the last 40 years and is projected to be the second leading cause of cancer death by 2030. Despite aggressive treatment regimens, prognosis for patients diagnosed with PDAC is very poor; PDAC has the lowest 5-year survival rate for any form of cancer in the United States (US). PDAC is very rarely detected in early stages when surgical resection can be performed. Only 20% of cases are suitable for surgical resection; this remains the only curative treatment when combined with adjuvant chemotherapy. Treatment regimens excluding surgical intervention such as chemotherapeutic treatments are associated with adverse effects and genetherapy strategies also struggle with lack of specificity and/or efficacy. The lack of effective treatments for this disease highlights the necessity for innovation in treatment options for patients diagnosed with early- to late-phase PDAC and immuno-oncolytic viruses (OVs) have been of particular interest since 2006 when the first oncolytic virus was approved as a therapy for nasopharyngeal cancers in China. Interest resurged in 2015 when T-Vec, an oncolytic herpes simplex virus, was approved in the United States for treatment of advanced melanoma. While many vectors have been explored, few show promise as treatment for pancreatic cancer, and fewer still have progressed to clinical trial evaluation. This review outlines recent strategies in the development of OVs targeting treatment of PDAC, current state of preclinical and clinical investigation and application.

Download Full-text